Abstarct
Prior attempts at personalizing anticancer treatments based on univariate tumor profiling (‘single gene variant’) for selection of monotherapy with targeted agents (‘single drug’) have generally yielded poor response rates. We report findings from the LIQUID IMPACT pilot trial where Multi-analyte Liquid Biopsy (MLB) profiling of circulating tumor analytes in peripheral blood was used to inform selection of personalized combination regimens in advanced refractory cancers. Among the 43 patients evaluable as per study protocol, 34 had targetable pathway activations. Partial Response (PR) was observed in 14 (41.1%) of the 34 patients with signaling pathway activation, including 5 (50%) of 10 cases with mTOR activation, 8 (44.4%) of 18 cases with activation of angiogenesis and 4 (50.0%) of 8 cases with EGFR / ERBB2 activation. PR was not reported among the 9 cases with no detectable pathway activation. Toxicities were manageable and there were no treatment related deaths. The study findings suggest that MLB may be able to inform safe and efficacious combination regimens in patients with advanced refractory cancers.
Competing Interest Statement
Rajnish Nagarkar, Timothy Crook, Nicholas Plowman, Andrew Gaya, Vijay Palwe, Prakash Pandit, Shruti Kate, Shirsendu Roy have no competing interests; Darshana Patil, Dadasaheb Akolkar, Navin Srivastava, Vineet Datta, Chirantan Bose, Sanket Patil, Sachin Apurwa, Ajay Srinivasan, are employees of the Study Sponsor; Rajan Datar is the founder of the Study Sponsor.
Clinical Trial
CTRI/2019/02/017548
Funding Statement
No external funding was obtained for this study. The entire study was funded by the Study Sponsor (DCG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All trials were approved by institutional review boards and ethics committees of the study sponsor (Datar Cancer Genetics, DCG) as well as clinical trial sites (HCG Manavata Cancer Centre, HCG-MCC). There is no approval number. The approval letters are available at: http://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=31265&EncHid=12285.74411&modid=1&compid=19 All trials were conducted in accordance with all applicable ethical guidelines and the Declaration of Helsinki. All study participants were previously counselled regarding study objectives, potential benefits and potential risks and provided signed written informed consent for participation in the trial.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets and supplementary material generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- ADL
- Activities of Daily Living
- AR
- Androgen Receptor
- BAM
- Binary Alignment/Map
- BED
- Browser Extensible Display
- CD45
- Cluster of Differentiation 45; Cell-Free
- DNA BCT
- Cell-Free DNA Blood Collection Tube
- C-ETACs
- Circulating Ensembles of Tumor Associated Cells
- CNV
- Copy Number Variations
- COSMIC
- Catalogue Of Somatic Mutations In Cancer
- CPM
- Counts Per Million
- CR
- Complete Response
- C-TACs
- Circulating Tumor Associated Cells
- CTCs
- Circulating Tumor Cells
- DAPI
- 4’,6-Diamidino-2-phenylindole dihydrochloride
- DCR
- Disease Control Rate
- ECOG
- Eastern Co-operative Oncology Group
- EDTA
- Ethylenediaminetetraacetic acid
- EGFR
- Epidermal Growth Factor Receptor
- EpCAM
- Epithelial Cell Adhesion Molecule
- ER
- Estrogen Receptor
- ERBB2
- Erb-B2 Receptor Tyrosine Kinase 2
- ETA
- Encyclopedic Tumor Analysis
- FDA
- Food and Drug Administration
- FDG PET-CT
- 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography
- HCS
- High-Content Screening
- HER2
- Human Epidermal Growth Factor Receptor 2
- HPE
- Histopathological Evaluation
- ICC
- Immunocytochemistry
- IGV
- Integrative Genomics Viewer
- IHC
- Immunohistochemistry
- IRB
- Institutional Review Boards
- ITT
- Intent To Treat
- IVD
- In-Vito Diagnostics
- LVEF
- Left Ventricular Ejection Fraction
- MLB
- Multi-analyte Liquid Biopsy
- MRI
- Magnetic Resonance Imaging
- mTOR
- mechanistic Target Of Rapamycin
- MTB
- Multidisciplinary Tumor Board
- NCI-CTCAE
- National Cancer Institute-Common Terminology Criteria for Adverse Events
- NCI-MATCH
- National Cancer Institute-Molecular Analysis for Therapy Choice
- NGS
- Next Genome Sequencing
- ORR
- Objective Response Rate
- OS
- Overall Survival
- panCK
- pan-Cytokeratin
- PBMCs
- Peripheral Blood Mononuclear Cells
- PET-CT
- Positron Emission Tomography–Computed Tomography
- PFS
- Progression Free Survival
- PIK3CA
- Phosphatidylinositol-4, 5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
- PR
- Partial Response
- QC
- Quality Control
- QoL
- Quality of Life
- RCC
- Renal Cell Carcinoma
- RECIST
- Response Evaluation Criteria in Solid Tumors
- SD
- Stable Disease
- SNV
- Single Nucleotide Variations
- SoC
- Standard of Care
- TAPUR
- Targeted Agent and Profiling Utilization Registry
- TMAP
- Torrent Mapping Alignment Program
- TR-AE
- Therapy Related Adverse Events
- UCSC
- University of California Santa Cruz
- VEGF
- Vascular Endothelial Growth Factor
- VEGFR
- Vascular Endothelial Growth Factor Receptor